About the Study
The LUMEOS study is sponsored by MeiraGTx, who is collaborating with Janssen Research & Development, LLC (JRD) on this and other inherited retinal disease (IRD) initiatives.
It is being conducted in countries around the world, including the United States (US), United Kingdom (UK), Canada, Belgium, Denmark, France, Germany, Ireland, Israel, Italy, Netherlands, Spain, and Switzerland.
The LUMEOS study is a phase 3 study and is now enrolling participants 3 years of age and older to investigate an innovative area of research called gene therapy in XLRP-RPGR.
“Phase 3” describes late-phase research to confirm and expand research after early phases of study. “Investigational” means the therapy has not been approved by any health authorities and is only for use in clinical trials.
Participants in the LUMEOS study will receive all study-related procedures, exams, and the investigational gene therapy at no cost. Travel assistance will be available.